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Abstract
Background: Colistin is used as last treatment option for pneumonia associated with multidrug-resistant (MDR)
Pseudomonas spp.. Literature about the best administration mode (inhalation versus parenteral treatment) is lacking.
Methods: A retrospective study of 20 intensive care patients with a pneumonia associated with MDR P. aeruginosa
receiving colistin sulphomethate sodium (Colistineb
®) between 2007 and 2009 was performed. A strain was considered
multidrug-resistant if it was resistant to at least 6 of the following antibiotics: piperacillin-tazobactam, ceftazidime,
cefepime, meropenem, aztreonam, ciprofloxacin, and amikacin. The administration mode, predicted mortality based on
the SAPS3 score, SOFA score at onset of the colistin treatment, clinical and microbiological response, and mortality
during the episode of the infection were analysed. The non parametric Kruskal-Wallis and Fisher’s Exact test were used
for statistical analysis of respectively the predicted mortality/SOFA score and mortality rate.
Results: Six patients received colistin by inhalation only, 5 were treated only parenterally, and 9 by a combination
of both administration modes. All patients received concomitant beta-lactam therapy. The mean predicted
mortalities were respectively 72%, 68%, and 69% (p = 0.91). SOFA scores at the onset of the treatment were also
comparable (p = 0.87). Clinical response was favorable in all patients receiving colistin by inhalation (6/6) and in
40% (2/5) of the patients receiving colistin parenterally (p = 0.06). In the patients with colistin administered both
via inhalation and parenterally, clinical response was favorable in 78% of the patients (7/9) (p = 0.27 as compared
to the treatment group receiving colistin only parenterally). When all patients with inhalation therapy were
compared to the group without inhalation therapy, a favorable clinical response was present in respectively 87%
and 40% (p = 0.06). In none of the patients, the Pseudomonas spp. was eradicated from the follow-up cultures.
All patients in the parenterally treated group died. None of the patients receiving colistin by inhalation, and 3 of 9
patients of the combination group eventually died (p = 0.002 and p = 0.03 respectively as compared to the group
receiving colistin only parenterally).
Conclusions: Aerosolized colistin could be beneficial as adjunctive treatment for the management of pneumonia
due to MDR P. aeruginosa.
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According to data from the US Centres for Disease con-
trol and Prevention (CDC) and the National Nosocomial
Infection Surveillance System (NNISS), Pseudomonas
aeruginosa i st h es e c o n dm o s tc o m m o nc a u s e( 1 7 % )o f
nosocomial pneumonia, and more importantly the most
common multidrug-resistant (MDR) gram-negative
pathogen causing pneumonia in hospitalized patients [1].
The increased prevalence of MDR and panresistant
P. aeruginosa and Acinetobacter spp. strains in multiple
parts of the world has created a new antibiotic therapeu-
tic void, leading to the use of the neglected class of poly-
myxins [1]. Until recently, the polymyxin class was
mainly used via inhalation to treat high-density respira-
tory tract colonization due to MDR P. aeruginosa in
patients with cystic fibrosis since this class was thought
to be unacceptably toxic when administered parenterally.
However, in recent years, colistin was observed to be
probably less toxic than previously proposed, and to offer
an acceptable efficacy for treatment of severe infections
due to MDR gram-negative bacteria [2]. Colistin is now
being used increasingly as a last treatment option for
treatment of nosocomial pneumonia with MDR gram-
negative bacteria [2].
We report our 2-year experience with the use of colistin
for the treatment of 20 patients, admitted to our intensive
care unit (ICU), who developed nosocomial pneumonia
associated with MDR P. aeruginosa.
Methods
This retrospective study was performed at the Antwerp
University Hospital, the 573 bed tertiary referral hospital
of the University of Antwerp. Pharmacy records were
reviewed to identify patients who were admitted to the
39 bed ICU, and were receiving colistin (Colistineb
®,
colistin sulphomethate sodium, Forest Laboratories,
Kent, UK) between June 2007 and June 2009 for therapy
of nosocomial pneumonia associated with MDR P. aeru-
ginosa. The primary objective was to compare the treat-
ment outcome of the pneumonia (clinical success;
mortality) between different colistin treatment groups
(parenteral treatment, inhalation treatment, combination
of parenteral and inhalation treatment). The study was
approved by the ethical committee (ref. 10/22/154) of the
hospital which judged that an informed consent was not
required. The following data were recorded for each
patient: age, sex, predicted mortality rate based on the
Simplified Acute Physiology3S c o r e( S A P S 3 )-s c o r e ,
Sequential Organ Failure Assessment (SOFA) - score at
admission to the ICU, and at the onset of the colistin
therapy, concomitant other infections, length and dosage
of colistin therapy, length of stay, time between admis-
sion and development of the pneumonia, simultaneous
use of other antibiotics, clinical and microbiological
response, and mortality during the episode of the infec-
tion [3,4]. An automated Patient Data Management sys-
tem (PDMS from iMD-soft) was used to collect most of
the data.
Diagnosis of nosocomial pneumonia was defined as
pneumonia that occured ≥ 48 hours after hospital admis-
sion. Pneumonia was diagnosed by the finding of a new
pulmonary infiltrate associated with at least two of the
following criteria: fever > 38°C, leukocytosis > 11,000
cells/mm
3, or purulent respiratory secretions [5]. Ventila-
tor associated pneumonia (VAP) was defined as a noso-
comial pneumonia in a patient with at least 48 hours of
mechanical ventilatory support [5]. The etiology of the
pneumonia was established by isolation of the organism
from blood cultures, or by culturing the organism from
endotracheal aspirates or mini-BALs irrespective of the
bacterial count.
The antibiotic regimen was determined by the primary
treating ICU physician on the basis of a standardised dose
regimen, the clinical follow up and response. Generally,
ICU physicians decided to treat patients arbitrarily with
parenterally administered colistin, together or without
inhalation, when they estimated that the infection was
“more severe” or if another infection focus with P. aerugi-
nosa was present. Patients were excluded for analysis if
they received ≤ 2 days of colistin therapy. A favorable clin-
ical response was defined as a resolution of presenting
symptoms and signs at the end of the treatment, and an
unfavorable clinical response was defined as persistence or
worsening of presenting symptoms and signs [6]. Favor-
able microbial response was defined as eradication of the
strain in a respiratory sample collected in the period of 1
day before until 7 days after discontinuation of the colistin
therapy.
Renal function was monitored by serial measurement of
the serum creatinine level. Creatinine at the onset of the
colistin therapy, maximal creatinine during the colistin
therapy, and prior renal replacement therapy (RRT) were
recorded. Renal failure was defined following the RIFLE
criteria as described by Hartzell et al [7]. Neurotoxicity
rates were not determined because of the lack of objective
criteria in our patients.
Bacterial isolates were identified by biochemical man-
ual testing methods. Susceptibility testing, including sus-
ceptibility for colistin, was performed using disk diffusion
testing (Sensitabs, Rosco diagnostics, Denmark) using
Clinical Laboratory and Standards Institute (CLSI) break-
points [8]. Multidrug-resistance was defined as non-sus-
ceptibility to at least six of the following antibiotics:
meropenem, amikacin, piperacillin-tazobactam, ceftazi-
dime, cefepime, aztreonam, and ciprofloxacin [9]. Quality
control was performed weekly in the study period since
2007 using ATCC 27853, and was always situated
between reference values.
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Page 2 of 8Colistin was administered intravenously at a dosage of
62500 IU/kg/day in 3 to 4 divided doses, and adjusted for
creatinine clearance if necessary. If colistin was adminis-
tered by inhalation, a standardised regimen of 2 mIU/aero-
sol t.i.d. was administered. In mechanically ventilated
patients, the efficient administration of the inhaled/aeroso-
lized colistin was guaranteed by the use of the standard
nebulizers for the ventilators used: Servo Ultra Nebulizer
145/345 for the Servo-I (Maquet, Solna, Sweden) and
the 84 12 935 nebulizer for the Dräger Evita 4 Ventilator
(Dräger, Lennik, Belgium). During spontaneous breathing,
optimal aerosol particle deposition was executed by stan-
dard delivery system (Cirrus drug nebulizer, Intersurgical,
Berkshire, UK).
All data were entered into a database and analyzed using
SAS 9.2. (SAS Institute Inc., North Carolina, USA). For the
continuous data, the non-parametric Kruskall Wallis test
was used. For the categorical data, we used the non-
parametric Fisher’s Exact test.
Results
Between June 2007 and June 2009, 20 patients who devel-
oped nosocomial pneumonia with MDR P. aeruginosa
were treated with colistin (> 2 days) at our ICU: 9 patients
received a combination therapy of both parenteral and
inhalation therapy, 6 were treated by inhalation only, and
5o n l yp a r e n t e r a l l y( T a b l e1 ) .M D RP. aeruginosa was
recovered from the respiratory tract in all patients and
additionally from the blood cultures in 2 patients. 4
patients were excluded from analysis since they received
colistin for ≤ 2 days. Ten of 20 strains were panresistant,
except for their susceptibility to colistin whereas 6 of 20
(30%) strains were susceptible to piperacillin-tazobactam,
3 (15%) to cefazidime, and 1 (5%) to amikacin. All patients
received combination therapy with beta-lactams, of which
piperacillin-tazobactam (n = 12), and meropenem (n = 9)
were most frequently used. Piperacillin-tazobactam was
switched to meropenem in one patient during colistin
therapy. Six out of 20 (30%) of the nosocomial pneumo-
nias were considered VAPs according to the definition [5].
Five out of 9 (56%) patients on combination therapy also
suffered from an infection associated with P. aeruginosa at
another focus (one intra-abdominal infection, and four
skin and soft tissue infections). In one of the 5 patients
with parenteral colistin therapy, an intra-abdominal infec-
tion with P. aeruginosa was present. One patient in the
inhalation group, developed an Enterobacter sepsis, which
was treated accordingly. The age, gender distribution, and
prior clinical condition were comparable between the
three different groups (Table 1). The mean predicted mor-
talities based on the SAPS3 score were respectively 72%,
68%, and 69% (p = 0.91) [4]. SOFA scores at admission
and at the onset of the treatment were also comparable (p
= 0.18 and p = 0.87 respectively) [4]. Mean treatment
durations were comparable and ranged from 19 to 27 days
(p = 0.87, Table 1). In all but one patient, follow up cul-
tures were performed. In none of them, microbiological
eradication was achieved (Table 2).
Clinical response was favorable in all patients treated by
inhalation only (6/6) and in 40% (2/5) of the patient trea-
ted only parenterally (p = 0.06). In the patients with the
combination colistin therapy, clinical response was favor-
able in 78% (7/9) (p = 0.27 as compared to the treatment
group with only parenterally administered colistin). When
all patients with inhalation therapy (inhalation only or
concomitant parenteral treatment) are compared to the
group without inhalation therapy, favorable clinical
response was present in respectively 87% and 40% (p =
0.06). Antibiotic therapy with colistin clinically failed in
2/10 versus 3/10 of patients with pneumonia associated
with MDR P. aeruginosa strains susceptible to respectively
only colistin versus colistine and at least one other antimi-
crobiological agent [Table 2]. All patients (5/5) died in the
group only receiving colistin parenterally. The mortality
was attributed directly to the pneumonia in 3 of 5 patients.
The two other patients died during therapy because of
1/an abdominal sepsis of unknown etiology, and 2/conco-
mitant severe pathology. In contrast, none of the patients
receiving colistin by inhalation only, and 3 of 9 (one case
fatality was directly linked to a cerebrovascular accident)
of the patients treated by the combination therapy, even-
tually died (p = 0.002 and p = 0.03 respectively as com-
pared to the group with colistin administered parenterally
only).
The mean duration of treatment was prolonged (> 14
days) in all three groups.
Approximately half of all patients in the different groups
received prior RRT (Table 1). Renal toxicity was absent in
all the patients (6/6) who did not receive prior RRT, and
only received colistin via inhalation. In the group of
patients with parenteral monotherapy who did not get
prior RRT, all patients (3/3) suffered from “Injury” accord-
ing to the RIFLE criteria [7] (Table 1). In the group with
the combination therapy, 1 of 5 suffered from “Failure”
because of a creatinine level of > 4 mg/dL. The failure in
this patient was however already present at the onset of
the colistin treatment.
Although neurotoxicity rates were not studied in our
analysis, no major insults on behalf of the colistin therapy
were described in the follow up notes of the different
patients. Some cases of critical illness neuropathy were
however noticed, but it was unclear whether there was a
relationship with the colistin treatment (data not shown).
Discussion
T h ec l i n i c a lr e s p o n s er a t eo f4 0 %( 2 / 5 )i nt h eg r o u p
with colistin administered parenterally only is in line
with results from similar studies in which response rates
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Page 3 of 8Table 1 Patient characteristics of the different treatment groups
Inhalation Parenteral +
Inhalation
Parenteral All patients treated by
Inhalation
p-value (difference between
groups?)
Number of patients (medical-surgical) 6 (1-5) 9 (5-4) 5 (3-2) 15 /
Age (years) 62.5 (15-84) 67.9 (59-76) 64.8 (46-
77)
65.7 (15-84) 0.91
Gender (Male %) 66.7% 77.8% 60.0% 58% 0.83
SOFA-score at admission 5.2 (2-9) 6.4 (0-15) 10.0 (3-13) 5.9 (2-15) 0.18
SOFA-score start colistin 6.3 (1-15) 6.7 (2-11) 6.0 (3-9) 6.5 (1-15) 0.87
SAPS3-score 80.7 (70-88) 80.8 (70-95) 79.0 (73-
85)
80.7 (70-95) 0.92
Length of stay (days) 55.0 (19-
103)
73.0 (16-141) 40.0 (29-
64)
65.8 (16-141) 0.16
Time between admission and development of the pneumonia
(days)
28.0 (7-75) 25.1 (8-68) 19.6 (13-
29)
16.7 (7-75) 0.99
Treatment duration (days) 27.2 (6-96) 19.3 (3-46) 21.0 (9-28) 22.5 (3-96) 0.87
Creatinine at onset colistin; RRT patients excluded (mg/dL) 0.8 (0.7-1.2) 2.3 (0.9-4.7) 0.9 (0.8-1.0) 1.6 (0.7-4.7) 0.39
Creatinine during colistin therapy; RRT patients exluded (mg/dL) 1.0(0.6-1.3) 2.6 (1.1-5.8) 1.9 (1.9-2.0) 1.9 (0.6-5.8) 0.36
Number of RRT patients 2/6 4/9 2/5 6/15 /
Data are presented as mean values with the range between brackets. RRT: renal replacement therapy.
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8Table 2 Outcome of the different treatment groups
Treatment
groups
Number of patients with P.
aeruginosa susceptible to
colistin AND one beta-lactam
Clinical failure
when only
susceptible to
colistin
Clinical failure when susceptible
to colistin and at least one
other antibiotic agent
Microbiological
failure
Favorable clinical response Mortality
Inhalation 4/6 0/2 0/4 5/5
1 no control
data
6/6 0/6
Inhalation +
Parenteral
3/9; 1/9 was susceptible to
aminoglycosides
1/5 1/4 9/9 7/9 3/9
Inhalation and
inhalation +
parenteral
8/15 1/7 1/8 14/14 13/15 3/15
Parenteral 2/5 2/3 1/2 5/5 2/5
p = 0.06 as compared to the
inhalation group
p = 0.27 as compared to the
parenteral + inhalation group
p = 0.07 as compared to both
the inhalation and inhalation +
parenteral group
5/5
p = 0.002 as compared to the
inhalation group;
p = 0.03 as compared to the
parenteral + inhalation group;
p = 0.003 as compared to both
the inhalation and inhalation +
parenteral group
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8of 17-73% were reported with the use of colistin in the
treatment of nosocomial pneumonia [1,10,11]. Response
rates with colistin therapy for treatment of nosocomial
pneumonia seem to be lower compared to treatment of
nonpulmonary infections, but are comparable to pre-
viously reported response rates of nosocomial pneumo-
nia treated with piperacillin, imipenem-cilastatin, and
ciprofloxacin [1]. The higher response rate of 100%
(6/6) (p = 0.06) in our group treated by inhalation of
colistin was probably related to several factors. First:
even though the clinical conditions (according to the
SOFA and SAPS3 score) of all patient groups were com-
parable, clinicians in our hospital more easily treated
patients parenterally when they estimated that the infec-
tion was “more severe” or if another infection focus with
P. aeruginosa was present. Unfortunately, no validated
score is available for the severity of nosocomial pneumonia
itself. Secondly, 4 out of 6 strains were susceptible to a
beta-lactam which was also part of the patients’ antibiotic
regimen. The efficacy of this combination therapy however
has not yet been proven. Third, the efficacy of aerosolized
colistin in pneumonia might have contributed to the
result. Pharmacokinetic studies have shown that a single
inhalation of 2 million IU of colistin leads to high sputum
concentrations of the drug even 12 h after the administra-
tion [12]. Guidelines by the American Thoracic Society
and the Infectious Diseases Society of America mention
that “aerosolized antibiotics may be considered as adjunc-
tive therapy in patients with MDR gram-negatives who are
not responding to systemic therapy” [13,14]. Although
only very few clinical studies are performed on aerosolized
colistin, results look promising: a case series of Falagas et
al. showed that 4/5 of the patients who developed a noso-
comial pneumonia (P. aeruginosa in 2 cases), and who
were treated with colistin aerosol in monotherapy, had a
favorable clinical evolution [15]. A second study showed a
cure rate of even 88% (7/8) in patients with a nosocomial
pneumonia treated with a combination therapy of parent-
eral colistin, and colistin via inhalation (P. aeruginosa in 1/
8 cases). This was higher, although not statistically signifi-
cant, than the 67% (30/45) cure rate in patients treated by
the parenteral route only [16]. Another small study of only
3 patients showed improvement after addition of aeroso-
lized colistin to the antipseudomonal beta-lactam therapy
[17]. In a fourth study, the role of inhalation therapy was
suggested as effective salvage therapy for treatment of
nosocomial pneumonia caused by MDR gramnegative
bacteria (P. aeruginosa in 16 of 19 patients) since therapy
with aerosolized polymyxin B led to improvement or cure
in 13 of 14 (93%) patients in whom previous parenteral
therapy with polymyxin B failed [18]. In a retrospective
cohort study, Korbila et al. found a cure rate of 80% (62/
78) in patients who received a combination of aerosolized
and parenteral colistin versus 61% (26/43) in patients who
received parenteral colistin alone (p 0.025) [19]. In a pro-
spective study from Michalopoulos et al, a clinical
response of VAP was observed in 50/60 (83.3%) patients
treated by inhalation therapy. In this study, fifty-seven of
the patients received concomitant intravenous treatment
with colistin or other antimicrobial agents [20] (Table 3).
In our study, 87% (13/15) of the patients treated with a
beta-lactam and colistin by inhalation with or without
concomitant parenteral treatment, had a favorable out-
come, which is higher than the 40% (2/5) when patients
only received a beta-lactam and parenteral colistin. Num-
bers were too low to show significance (p = 0.07). How-
ever, significance was reached in the mortality rates (3/15
versus 5/5 respectively; p = 0.003), even though the pre-
dicted mortality according to the SAPS-3 score, and the
clinical condition according to the SOFA-score at admis-
sion and at the onset of the colistin treatment, were com-
parable. In contrast to the clinical response, no
microbiological eradication was noticed in any of the
patients. Low ratios of failing microbiological eradication
were found by Montero et al. (eradication in only 7 of 13
treated patients for pneumonia). They found that coloniza-
tion with MDR Pseudomonas prior to infection was an
indepent risk factor for persistent colonization [21].
The prolonged colistin treatment was mainly due to the
fact that colistin was already the last treatment option, and
the clinical response was unfavourable in 5 of 20 patients.
In addition, the absence of serious adverse events and the
persistent colonization of the respiratory tract may have
played a role.
Table 3 Summary of available studies on colistin administered by inhalation versus administered parenterally
Study name Route of administration % of success
Falagas [15] inhalation 80% (4 of 5)
Michalopoulos [16] inhalation + parenteral
parenteral
88% (7 of 8)
67% (30 of 45)
Hamer [17] inhalation + parenteral beta-lactam therapy 100% (3 of 3)
Pereira [18] inhalation after failing parenteral therapy 93% (13 of 14)
Korbila [19] inhalation + parenteral
parenteral
80% (62 of 78)
61% (26 of 43)
Michalopoulos [20] inhalation + parenteral (57 of 60 patients)
inhalation (3 patients)
83% (50 of 60)
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Page 6 of 8Recent studies reported nephrotoxicity rates of 8% to 36%
[2]. In our case series, 100% (3/3) of patients treated by par-
enterally administered colistin, who were not receiving
prior RRT, developed nephrotoxicity to be classified as
“Injury” according to the RIFLE criteria [7] (Table 1). Of
those 3 patients, mean serum creatinine at the onset of the
colistin therapy raised from 0.9 mg/dL to a maximum of
1.9 mg/dL during therapy. Since all 3 patients died, follow
up of the creatinine levels was not possible in this sub-
group. We hypothesise that the high rate of renal injury in
this group was not attributable to colistin only, but may
also have resulted from renal damage in the setting of a fail-
ing therapy, eventually leading to mortality in all patients.
In the group with the combination therapy, in which clini-
cal response was favorable in 78% of the patients (7/9),
renal “Failure” was only present in one patient according to
the RIFLE criteria. The failure in the patient was however
already present before the colistin was administered. Simi-
larly, Falagas et al. found a median rise in creatinine levels
of only 0.25 mg/dL during prolonged (mean: 43 days) par-
enteral colistin treatment in 19 courses. Moreover, the
levels returned close to baseline at the end of the treatment
(0.1 mg/dL). In the group with inhalation therapy, none of
the patients developed nephrotoxicity, which was probably
attributed to the more “topical” distribution of colistin
when delivered by inhalation [22].
Shortcomings and possible confounders in our study
were 1/the use of a single centre retrospective analysis
on small numbers; 2/the difficulty to discriminate
between patients that were infected versus colonized by
Pseudomonas spp.; 3/the inability of including time to
appropriate therapy in the different treatment groups; 4/
the administration of concomitant antimicrobial therapy.
Conclusion
We conclude that aerosolized colistin appears to be a pro-
mising adjunct when used in combination with parenteral
therapy (colistin or beta-lactams) over parenteral therapy
alone. Since colistin is a last-line drug for infections with
highly resistant Pseudomonas spp., there is an urgent need
for randomized, controlled trials to further delineate its
role in the ICU setting.
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